|
|
|
|
|
|
|
|
UNC Kidney Center: thrombotic microangiopathy
~~~~~~~~~~~~~~~~~~
Is Renal Thrombotic Angiopathy a Potential Problem in the Chronic Treatment of Ovarian Cancer?
"Treatments for recurrent ovarian cancer result in clinical
benefit and prolongation of survival times. However, our findings suggest that platinums, PLD (in large cumulative doses), bevacizumab, and possibly gemcitabine may result in cumulative kidney damage. Awareness of these long-term complications should open the way for studies on treatment strategies designed to minimize renal complications."
Abstract
Abstract Background and Objective
Ovarian
cancer is usually diagnosed at an advanced stage, with most patients
undergoing surgery followed by platinum- and
taxane-based chemotherapy. After initial
clinical remission, the majority recur, leading to additional
treatments, including
not only platinums and taxanes but also
pegylated liposomal doxorubicin (PLD), gemcitabine, topotecan, and, more
recently,
bevacizumab, which may extend survival times.
PLD, in particular, has been extensively studied by our group, with
encouraging
therapeutic results. We, however, observed
instances of chronic kidney disease (CKD) developing among patients who
received
long-term treatment for recurrent ovarian
cancer. To document the frequency and contributing factors to the
emergence of CKD,
we initiated a retrospective review at two
institutions.
(Kidney damage was defined by pathologic abnormalities
or markers of damage, including abnormalities on blood
and urine tests and radiologic studies.)
(Kidney damage was defined by pathologic abnormalities
or markers of damage, including abnormalities on blood
and urine tests and radiologic studies.)
Patients and Methods.
Fifty-six
consecutive patients with recurrent ovarian cancer receiving treatment
at New York University Cancer Institute were
reviewed for the presence of renal disease in
1997–2010. At Shaare Zedek Medical Center, 73 consecutive patients with
ovarian
cancer were reviewed in 2002–2010. Patients were
diagnosed with CKD if they had an estimated GFR <60 mL/minute per
1.73 m2 for >3 months and were staged according to the National Kidney Foundation guidelines.
Results.
Thirteen
patients (23%) developed stage ≥3 CKD. Three patients had renal biopsies
performed that showed thrombotic microangiopathy.
Conclusions.
CKD (chronic kidney disease) is emerging as a potential long-term consequence of current chemotherapy for recurrent ovarian cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.